Adam Levy compensation by year
Viridian Therapeutics Summary Compensation Table · all 2 fiscal years held| Component | FY2017 | FY2018 |
|---|---|---|
| Salary | $300,000 | $345,000 |
| Bonus | $108,000 | $82,800 |
| Stock awards | $0 | $0 |
| Option awards | $704,149 | $440,818 |
| Non-equity incentive | $0 | $0 |
| Pension and deferred compensation | $0 | $0 |
| All other | $0 | $0 |
| Total | $1,112,149 | $868,618 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Viridian Therapeutics, Inc. DEF 14A filed May 3, 2019, accession 0001590750-19-000021, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Viridian Therapeutics, Inc. filed document, accession 0001590750-19-000021. Every figure is read from that document and cited to the page and table it appears in. Filed May 3, 2019.
Equity holdings
unvested awards at FY2018 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 57,494 | — | $1.05 |
| Option | 47,396 | — | $11.01 |
| Option | 61,667 | — | $7.50 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Viridian Therapeutics, Inc.'s FY2018 proxy; value at the fiscal year-end close, as the company printed it.
Viridian Therapeutics’s named executive officers, FY2018
as the company reported each| Named executive officer | Role | FY2018 total |
|---|---|---|
| William Marshall | Chief Executive Officer and President | $1,987,005 |
| Paul Rubin | Executive Vice President, Research and Development | $976,769 |
| Adam Levy · this page | Chief Business Officer | $868,618 |
| Jason Leverone | Chief Financial Officer | $824,667 |
The full Viridian Therapeutics compensation record
free company briefThis page is one person within Viridian Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Viridian Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Viridian Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.